VAYEMAhttps://vayema.clinic/therapies/medications-alcohol-use-disorder/

Medical treatment

Medications for Alcohol Use Disorder: Options and FAQs

Explore acamprosate, naltrexone, disulfiram and other alcohol-treatment medicines, with guidance on assessment, withdrawal, monitoring and ongoing recovery.

Clinically reviewed Dr. Sarah Boss, MD

Medicines can help some people reduce alcohol use, maintain abstinence or manage withdrawal safely. These are different treatment goals, and the same medicine is not suitable for all of them. A prescription should be chosen through assessment and reviewed as part of a broader recovery plan.

Common options for ongoing alcohol treatment include acamprosate, naltrexone and disulfiram. Nalmefene is used in some jurisdictions for a defined group seeking to reduce consumption. The appropriate choice depends on drinking pattern, physical health, other medicines, previous treatment and personal preferences.

What can alcohol-treatment medication do?

The National Institute on Alcohol Abuse and Alcoholism explains that medicines can support stopping or reducing drinking and avoiding a return to harmful use. They are tools for treatment, not a substitute for understanding the person’s circumstances.

A useful consultation identifies what the medicine is meant to change. Is the priority maintaining abstinence after withdrawal, reducing heavy-drinking episodes or managing an immediate medical risk?

The alcohol-use disorder guide explains the wider care pathway. Treatment should not be judged solely by whether someone has been given a tablet.

Withdrawal medicines are a separate category

Alcohol withdrawal can cause seizures, severe confusion and other dangerous complications. Medicines used to prevent or manage these complications are not the same as longer-term relapse-prevention treatments.

The UK clinical guidelines distinguish withdrawal management, thiamine treatment and medicines intended to support longer-term change. Acamprosate or naltrexone should not be mistaken for protection against a withdrawal seizure.

People who may be physically dependent should seek medical advice before abruptly stopping. The medically assisted withdrawal guide covers assessment and the choice of a safe setting.

Acamprosate: supporting abstinence

Acamprosate is generally considered when the goal is to maintain abstinence after stopping alcohol. It is taken according to a prescribed schedule rather than used as an emergency response to a craving.

NICE guidance includes acamprosate as an option after successful withdrawal for moderate or severe dependence, alongside an appropriate psychological intervention.

Kidney function, other health concerns and the feasibility of the medication routine need consideration. Ask what benefit to look for, what adverse effects should be reported and what the plan is if drinking resumes. Do not change the regimen independently after a setback.

Naltrexone: reducing the reinforcing effects of drinking

Naltrexone blocks opioid receptors and can help reduce alcohol craving or heavy drinking for some people. It does not cause the same alcohol reaction as disulfiram, and it does not make intoxication or alcohol-related harm impossible.

Tell the prescriber about opioid pain medicines, opioid-use disorder treatment or non-prescribed opioid use. Naltrexone can interfere with opioid pain relief and can trigger withdrawal when opioids remain in the body.

SAMHSA’s naltrexone information also highlights the need to discuss liver health and other clinical risks. Tablet and injectable availability differs between countries, so confirm the exact preparation being proposed.

Disulfiram: an abstinence-focused deterrent

Disulfiram changes the way alcohol is metabolised. Drinking while taking it can cause an unpleasant and potentially dangerous reaction, including flushing, nausea, palpitations and more serious cardiovascular effects.

It is not a medicine to test by deliberately drinking, and it should never be given covertly or used to punish someone. The person needs to understand the treatment, agree to it and know about alcohol hidden in some medicines or other products.

The prescriber should assess medical suitability, explain monitoring and discuss support with taking it. Involvement of a partner or family member should be agreed and safe, not turned into surveillance or conflict.

Nalmefene and a reduction goal

NICE recommends nalmefene as an option for selected adults with alcohol dependence and a persistently high drinking-risk level who do not have physical withdrawal symptoms and do not need immediate detoxification. It is provided with continuing psychosocial support.

This is a specific indication, not a general recommendation for anyone who drinks more than intended. The clinician must first determine whether a reduction plan is appropriate or whether abstinence and withdrawal care are safer.

Nalmefene used in alcohol treatment should not be confused with emergency opioid-overdose products carrying the same medicine name in other settings. Formulation, indication and local authorization matter.

How the treatment goal is agreed

For many people with significant dependence or alcohol-related illness, abstinence is the safest goal. Other people may begin with a reduction or harm-reduction plan. The discussion should be honest about risk while still offering support when someone is uncertain about stopping completely.

The NHS alcohol-use disorder information recognizes both support to stop and help to reduce harm. A disagreement about the goal should not end the conversation about care.

Ask what the proposed goal means in practical terms and when it will be reviewed. Vague intentions are harder to translate into a useful prescribing and support plan.

What should the assessment include?

Describe the amount and pattern of drinking as accurately as possible, including morning use, periods without alcohol and what happens when you try to stop. Previous withdrawal seizures or severe confusion are especially important to disclose.

The clinician should also consider liver and kidney health, nutrition, pregnancy, mood, sleep and other substance use. Bring a current medication list, including non-prescription products.

Tests should have a clear purpose. Ask what is being checked, who will review the results and how they affect the treatment choice rather than assuming that one normal blood test establishes overall safety.

What does research tell us?

The COMBINE randomised trial examined medicines and behavioral interventions for alcohol dependence. Naltrexone with medical management improved drinking outcomes in the study, while acamprosate did not show an additional benefit in that particular trial.

That result should not be turned into a claim that acamprosate never helps. Guidelines consider a wider evidence base, and differences in participants, abstinence before treatment and the support provided can affect results.

The practical question is which option has a reasonable evidence base for your circumstances and how its value will be tested. No medicine guarantees recovery, and a poor response to one does not mean that all treatment has failed.

Monitoring and managing adverse effects

Agree follow-up arrangements before starting. Reviews should consider drinking, craving, functioning, adherence and unwanted effects, rather than simply ask whether a prescription is needed again.

Report new illness, marked mood changes, yellowing of the skin or eyes, significant abdominal symptoms or other reactions highlighted in the patient leaflet. Severe symptoms require urgent assessment.

Different medicines have different precautions. Obtain specific advice about missed doses, illness, alcohol exposure and when to contact the prescriber. Do not rely on another person’s experience of a different treatment.

Medication alongside psychological support

A medicine may reduce one barrier to change while other difficulties remain. Motivational enhancement therapy can help clarify goals, while CBT-based relapse prevention examines triggers, coping responses and recovery after setbacks.

Support may also involve routines, relationships, housing or peer connection. A person who drinks after conflict may need more than advice to remember their prescription.

Family participation can be helpful when wanted and safe. When there is coercion or abuse, a shared session or supervised medication arrangement may be inappropriate and requires separate consideration.

Other medicines and co-occurring conditions

Specialists sometimes consider off-label medicines, but the rationale and uncertainties should be explained. A drug being discussed online or studied in a small trial does not establish routine suitability.

Depression, anxiety and other mental health problems may need treatment in their own right. An antidepressant should not be assumed to treat alcohol dependence simply because both conditions are present.

The co-occurring conditions guide explains coordinated care. Significant suicidal thoughts or severe mental illness need appropriate assessment rather than postponement until drinking has completely resolved.

Setbacks, duration and continuity

A return to drinking is a reason to review the plan and immediate safety, not to hide from the treating team. The response depends on the medicine and circumstances; disulfiram exposure, for example, creates different concerns from a missed appointment.

Discuss treatment duration through regular review of benefit, tolerability and risk. A predetermined course length should not replace an individual decision.

Before moving between services or traveling, establish who will prescribe, provide follow-up and respond to problems. An interruption caused by unclear responsibility is avoidable when the handover is planned.

Frequently asked questions about alcohol medicines

Do these medicines make drinking safe?

No. They do not cancel alcohol’s effects on judgment, driving, organs or overdose risk. Their purpose is to support a treatment goal, not to provide protection for unrestricted drinking.

Will all alcohol medicines make me sick if I drink?

No. Disulfiram is the medicine specifically associated with an alcohol reaction. Acamprosate and naltrexone work differently. Ask for instructions for your own prescription rather than treating them as interchangeable.

Can I start medication instead of having a detox assessment?

No. Possible physical dependence and withdrawal risk need assessment first. Relapse-prevention medicines do not replace treatment for seizures, delirium or other acute withdrawal complications.

Can I take naltrexone with opioid pain relief?

Tell the prescriber about all opioid use before starting. Naltrexone can block opioid effects and may precipitate withdrawal. Pain treatment and any planned surgery need a coordinated medical plan.

Does needing medication mean I lack willpower?

No. Medication is a treatment option, not a measure of character. The useful question is whether it helps you make and sustain changes safely, alongside support that fits your life.

What happens if I drink again?

Contact the clinical team and follow the medicine-specific safety instructions. Seek urgent help for serious symptoms. A setback should lead to reassessment and support rather than an assumption that recovery is no longer possible.

Discussing your options

A clinical assessment can clarify withdrawal risk and longer-term treatment choices. Contact VAYEMA to discuss your concerns and an appropriate next step.

Sources and further reading

  1. NIAAA: Finding alcohol treatment
  2. NICE CG115: Alcohol treatment recommendations
  3. UK clinical guidelines: Pharmacological interventions
  4. NICE: Nalmefene
  5. SAMHSA: Naltrexone
  6. COMBINE randomised clinical trial
  7. NHS: Alcohol-use disorder

Related conditions and concerns

These links explain the wider care context. They are not a recommendation that this approach is suitable for everyone with the condition. Use the condition treatment guide to understand alternatives and the role of clinical assessment.

Choosing the right support

Start with your needs, not a therapy label.

An assessment can help clarify what you are experiencing, compare appropriate options and establish whether a suitably trained professional is available. This guide does not confirm that VAYEMA offers the approach.

Discuss an assessment

This library is not an emergency service. If you cannot keep yourself or someone else safe, contact local emergency services or attend the nearest emergency department.

Start with a private assessment.

Private and discreet from the first conversation. Tell us how and when you prefer to be contacted, using contact details and practical preferences only.

VAYEMA

What would you like to explore?

Enter at least two characters to search.

VAYEMA

Private mental health care

Let us help you find the next step.

You do not need to choose a clinician or treatment program in advance.

Private and discreet from the first conversation. Tell us how and when you prefer to be contacted, using contact details and practical preferences only.

This form sends your information by email to [email protected]. Please do not include symptoms, medical histories, medication details or clinical documents.

Preferred session format

Select any that suit you.

Your preferred format, practitioner availability and any fees are discussed before an appointment is agreed. For urgent help, contact local emergency services rather than waiting for this form.

Prefer email? Contact [email protected].

Read our privacy information before sharing personal information.

VAYEMAYOUR NEXT STEP
Automated service guide Not clinical care English

You do not have to figure it out alone.

Explore what support could look like, at your own pace. You do not need a diagnosis or the right words to begin.